vs
Side-by-side financial comparison of Third Coast Bancshares, Inc. (TCBX) and Vericel Corp (VCEL). Click either name above to swap in a different company.
Vericel Corp is the larger business by last-quarter revenue ($92.9M vs $57.7M, roughly 1.6× Third Coast Bancshares, Inc.). Third Coast Bancshares, Inc. runs the higher net margin — 28.4% vs 25.0%, a 3.4% gap on every dollar of revenue. Over the past eight quarters, Vericel Corp's revenue compounded faster (34.6% CAGR vs 17.5%).
Third Coast Bancshares, Inc. is a regional financial holding company headquartered in the U.S. Gulf Coast region. It provides a full suite of commercial and retail banking services including deposit products, business and consumer loans, mortgage services, and wealth management solutions, serving local small and medium-sized enterprises, individual consumers, and community clients across Texas and surrounding areas.
Vericel Corporation is a publicly traded American biopharmaceutical company which was known prior to October 2014 as Aastrom Bio. Aastrom Bio was formed in 1989 in Ann Arbor, Michigan.
TCBX vs VCEL — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $57.7M | $92.9M |
| Net Profit | $16.4M | $23.2M |
| Gross Margin | — | 78.7% |
| Operating Margin | — | 24.1% |
| Net Margin | 28.4% | 25.0% |
| Revenue YoY | — | 23.3% |
| Net Profit YoY | 20.5% | 17.3% |
| EPS (diluted) | $0.88 | $0.46 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $57.7M | — | ||
| Q4 25 | $56.5M | $92.9M | ||
| Q3 25 | $54.5M | $67.5M | ||
| Q2 25 | $52.0M | $63.2M | ||
| Q1 25 | $45.9M | $52.6M | ||
| Q4 24 | $46.3M | $75.4M | ||
| Q3 24 | $42.9M | $57.9M | ||
| Q2 24 | $41.7M | $52.7M |
| Q1 26 | $16.4M | — | ||
| Q4 25 | $17.9M | $23.2M | ||
| Q3 25 | $18.1M | $5.1M | ||
| Q2 25 | $16.7M | $-553.0K | ||
| Q1 25 | $13.6M | $-11.2M | ||
| Q4 24 | $13.7M | $19.8M | ||
| Q3 24 | $12.8M | $-901.0K | ||
| Q2 24 | $10.8M | $-4.7M |
| Q1 26 | — | — | ||
| Q4 25 | — | 78.7% | ||
| Q3 25 | — | 73.5% | ||
| Q2 25 | — | 73.7% | ||
| Q1 25 | — | 69.0% | ||
| Q4 24 | — | 77.6% | ||
| Q3 24 | — | 71.9% | ||
| Q2 24 | — | 69.5% |
| Q1 26 | — | — | ||
| Q4 25 | 38.1% | 24.1% | ||
| Q3 25 | 41.9% | 5.1% | ||
| Q2 25 | 40.5% | -3.2% | ||
| Q1 25 | 37.8% | -24.3% | ||
| Q4 24 | 38.7% | 24.5% | ||
| Q3 24 | 37.9% | -4.3% | ||
| Q2 24 | 34.1% | -11.5% |
| Q1 26 | 28.4% | — | ||
| Q4 25 | 31.7% | 25.0% | ||
| Q3 25 | 33.1% | 7.5% | ||
| Q2 25 | 32.2% | -0.9% | ||
| Q1 25 | 29.6% | -21.4% | ||
| Q4 24 | 29.7% | 26.3% | ||
| Q3 24 | 29.8% | -1.6% | ||
| Q2 24 | 25.9% | -8.9% |
| Q1 26 | $0.88 | — | ||
| Q4 25 | $1.02 | $0.46 | ||
| Q3 25 | $1.03 | $0.10 | ||
| Q2 25 | $0.96 | $-0.01 | ||
| Q1 25 | $0.78 | $-0.23 | ||
| Q4 24 | $0.80 | $0.40 | ||
| Q3 24 | $0.74 | $-0.02 | ||
| Q2 24 | $0.63 | $-0.10 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $137.5M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $650.5M | $354.6M |
| Total Assets | $6.6B | $488.0M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $175.2M | $137.5M | ||
| Q3 25 | $116.4M | $135.4M | ||
| Q2 25 | $113.1M | $116.9M | ||
| Q1 25 | $219.0M | $112.9M | ||
| Q4 24 | $371.2M | $116.2M | ||
| Q3 24 | $258.2M | $101.7M | ||
| Q2 24 | $241.8M | $102.5M |
| Q1 26 | $650.5M | — | ||
| Q4 25 | $531.0M | $354.6M | ||
| Q3 25 | $513.8M | $321.9M | ||
| Q2 25 | $496.1M | $306.8M | ||
| Q1 25 | $479.8M | $295.5M | ||
| Q4 24 | $460.7M | $292.0M | ||
| Q3 24 | $450.5M | $257.5M | ||
| Q2 24 | $435.0M | $243.0M |
| Q1 26 | $6.6B | — | ||
| Q4 25 | $5.3B | $488.0M | ||
| Q3 25 | $5.1B | $453.3M | ||
| Q2 25 | $4.9B | $435.6M | ||
| Q1 25 | $4.9B | $424.6M | ||
| Q4 24 | $4.9B | $432.7M | ||
| Q3 24 | $4.6B | $390.4M | ||
| Q2 24 | $4.5B | $376.8M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $15.0M |
| Free Cash FlowOCF − Capex | — | $12.8M |
| FCF MarginFCF / Revenue | — | 13.8% |
| Capex IntensityCapex / Revenue | — | 2.4% |
| Cash ConversionOCF / Net Profit | — | 0.65× |
| TTM Free Cash FlowTrailing 4 quarters | — | $24.7M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $50.8M | $15.0M | ||
| Q3 25 | $20.7M | $22.1M | ||
| Q2 25 | $13.9M | $8.2M | ||
| Q1 25 | $10.5M | $6.6M | ||
| Q4 24 | $35.1M | $22.2M | ||
| Q3 24 | $22.0M | $10.2M | ||
| Q2 24 | $7.3M | $18.5M |
| Q1 26 | — | — | ||
| Q4 25 | — | $12.8M | ||
| Q3 25 | — | $19.5M | ||
| Q2 25 | — | $81.0K | ||
| Q1 25 | — | $-7.6M | ||
| Q4 24 | $33.4M | $8.5M | ||
| Q3 24 | — | $-9.2M | ||
| Q2 24 | — | $1.8M |
| Q1 26 | — | — | ||
| Q4 25 | — | 13.8% | ||
| Q3 25 | — | 28.8% | ||
| Q2 25 | — | 0.1% | ||
| Q1 25 | — | -14.5% | ||
| Q4 24 | 72.1% | 11.2% | ||
| Q3 24 | — | -15.9% | ||
| Q2 24 | — | 3.4% |
| Q1 26 | — | — | ||
| Q4 25 | — | 2.4% | ||
| Q3 25 | — | 3.9% | ||
| Q2 25 | — | 12.9% | ||
| Q1 25 | — | 27.0% | ||
| Q4 24 | 3.8% | 18.3% | ||
| Q3 24 | — | 33.5% | ||
| Q2 24 | — | 31.8% |
| Q1 26 | — | — | ||
| Q4 25 | 2.84× | 0.65× | ||
| Q3 25 | 1.15× | 4.35× | ||
| Q2 25 | 0.83× | — | ||
| Q1 25 | 0.77× | — | ||
| Q4 24 | 2.56× | 1.12× | ||
| Q3 24 | 1.72× | — | ||
| Q2 24 | 0.68× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
TCBX
| Net Interest Income | $53.6M | 93% |
| Noninterest Income | $4.0M | 7% |
VCEL
| MACI Implants And Kits | $84.1M | 90% |
| Other | $8.8M | 10% |
